Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study

Wortsman, Ximena; Barrio‐Díaz, Pablo Del; Meza‐Romero, Rodrigo; Poehls-Risco, Christine; Vera‐Kellet, Cristián

doi:10.1016/j.jaad.2017.08.018

Cited by 17 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of recent clinical trials have explored additional disease indications that might benefit from the vasodilatory properties of PDE5i's. A cream version of sildenafil has recently been tested in a Phase II study examining female sexual arousal disorder (Table 3) as well as a study in which improved blood flow in patients with secondary Raynaud phenomenon was observed (153). International consortiums are testing sildenafil in intrauterine growth restriction in hopes that the vasodilatory properties of the drug will improve uteroplacental perfusion and, thus, fetal growth (154,155).…”

Section: Pde5 Inhibitorsmentioning

confidence: 99%

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

Baillie

Tejeda

Kelly

2019

Nat Rev Drug Discov

260

295

View full text Add to dashboard Cite

show abstract

Section: Pde5 Inhibitorsmentioning

confidence: 99%

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

Baillie

Tejeda

Kelly

2019

Nat Rev Drug Discov

260

295

View full text Add to dashboard Cite

show abstract

“…In a physiological study, topical glyceryl trinitrate (GTN) increased blood flow at the ulcer site [ 53 ] and topical treatments for Raynaud's phenomenon are at long last receiving attention. [ 54,55 ] Regarding "non‐drug" local treatments, a recent pilot study demonstrated the feasibility of low‐level light therapy and pointed to a possible therapeutic effect. [ 56 ] Research is urgently required into (a) topical formulations of vasoactive treatments and (b) various procedural treatments including light‐based therapies, botulinum toxin injections [ 57 ] (expanding on previous studies by including patients with early disease), different debridement techniques, and autologous fat grafting/local subcutaneous injection of adipose‐derived stromal vascular fraction [ 58,59 ] (results of a randomised controlled trial ClinicalTrials.gov NCT02558543 are yet to be reported in full). Can we prevent ulcers developing?…”

Section: Digital Ulcersmentioning

confidence: 99%

Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint)

Herrick

Shukla

Watson

2020

Experimental Dermatology

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a multisystem connective tissue disease associated with high morbidity and mortality: its clinical features result from a combination of fibrosis and ischaemia. Clinicians and scientists have, understandably, tended to focus on its life-threatening internal organ complications [1] which include interstitial lung disease, pulmonary hypertension, and gastro-intestinal, cardiac and renal involvement ("scleroderma renal

show abstract

“…Non-significant improvement in clinical symptoms compared to placebo, with substantial heterogeneity in patient response (Roustit, Giai et al, 2018). Significant improvement in digital blood flow compared to topical nifedipine cream (Wortsman, Del Barrio-Díaz et al, 2018).…”

Section: Sildenafil Lille University Hospital Francementioning

confidence: 99%

Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease

Tzoumas

Farrah

Dhaun

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension. In the last decade, accumulating evidence suggests that PDE5Is may confer a wider range of clinical benefits than was previously recognised. This has led to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in conditions such as hypertension, myocardial infarction, stroke, peripheral arterial disease, chronic kidney disease and diabetes mellitus. Here, we review the pharmacological properties and established licensed uses of this class of drug, along with emerging therapeutic developments and possible future indications. 1 | INTRODUCTION Few other pharmaceutical agents have had a history as serendipitous as the class of PDE type 5 inhibitors (PDE5Is; Figure 1). Developed over 30 years ago, initially for cardiovascular indications, PDE5Is emerged as a revolutionary treatment for erectile dysfunction (ED), licensed in 1998 (Goldstein, Lue et al., 1998). Further investigation of their effects on pulmonary arterial pressure culminated in their approval for the treatment of pulmonary arterial hypertension (PAH) in 2005 (Galiè, Ghofrani et al., 2005). Early reports of fatal cardiovascular events in patients prescribed a PDE5I delayed wider research into their therapeutic benefits, but it soon became apparent that these adverse events reflected the complex nature of patients initially receiving the drug and their high level of cardiovascular risk, rather than the properties of the drug itself (Cheitlin, Hutter et al., 1999;

show abstract

Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study

Cited by 17 publications

References 3 publications

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint)

Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease

Contact Info

Product

Resources

About